Marten J. Poley - Erasmus Universiteit Rotterdam

Introduction 1320. Oostenbrink JB, Bouwmans CAM,Koopmanschap MA, Rutten FFH: Manualfor costing research. Methods andguideline prices for economicevaluations in health care. 2004Updated edition [in Dutch]. Diemen:Health Care Insurance Board; 2004.21. Canadian Coordinating Office for HealthTechnology Assessment: A guidancedocument for the costing process.Version 1.0. Ottawa: CanadianCoordinating Office for HealthTechnology Assessment (CCOHTA);1996.22. Canadian Coordinating Office for HealthTechnology Assessment: Guidelines foreconomic evaluation ofpharmaceuticals: Canada. 2nd edition.Ottawa: Canadian Coordinating Officefor Health Technology Assessment(CCOHTA); 1997.23. Commonwealth Department of Healthand Ageing: Guidelines for thepharmaceutical industry on preparationof submissions to the PharmaceuticalBenefits Advisory Committee. Canberra:Commonwealth Department of Healthand Ageing; 2002.24. National Institute for ClinicalExcellence: Guidance for manufacturersand sponsors. Technology appraisalsprocess series no. 5. London: NationalInstitute for Clinical Excellence; 2001.25. Norwegian Medicines Agency:Norwegian guidelines forpharmacoeconomic analysis inconnection with applications forreimbursement. Available at:http://www.legemiddelverket.no/eng/reg/pharmacoeconomic-analysisguidelines.htm.Accessed August 16,2005.26. Rovira J, Antoñanzas F: Economicanalysis of health technologies andprogrammes. A Spanish proposal formethodological standardisation.Pharmacoeconomics 1995; 8(3): 245-252.27. Hout BAv: Whom and how to treat:weighing the costs and effects. Scand JGastroenterol Suppl 2003; (239): 3-10.28. Meltzer D: Accounting for future costsin medical cost-effectiveness analysis. JHealth Econ 1997; 16: 33-64.29. Russell LB: Is prevention better thancure? Washington D.C.: The BrookingsInstitution; 1986.30. Weinstein MC, Siegel JE, Gold MR,Kamlet MS, Russell LB:Recommendations of the Panel on Cost-Effectiveness in Health and Medicine.JAMA 1996; 276(15): 1253-1258.31. Etzioni R, Ramsey SD, Berry K, BrownM: The impact of including futuremedical care costs when estimating thecosts attributable to a disease: acolorectal cancer case study. HealthEcon 2001; 10(3): 245-256.32. Manns B, Meltzer D, Taub K, DonaldsonC: Illustrating the impact of includingfuture costs in economic evaluations:an application to end-stage renaldisease care. Health Econ 2003;12(11): 949-958.33. Stone PW, Chapman RH, Sandberg EA,Liljas B, Neumann PJ: Measuring costsin cost-utility analyses. Variations in theliterature. Int J Technol Assess HealthCare 2000; 16(1): 111-124.34. Brouwer WBF, Koopmanschap MA,Rutten FFH: Patient and informalcaregiver time in cost-effectivenessanalysis. A response to therecommendations of the WashingtonPanel. Int J Technol Assess Health Care1998; 14(3): 505-513.35. Koopmanschap MA, Rutten FFH, IneveldBMv, Roijen Lv: The friction costmethod for measuring indirect costs ofdisease. J Health Econ 1995; 14(2):171-189.36. Johannesson M, Karlsson G: The frictioncost method: a comment. J Health Econ1997; 16(2): 249-255.